{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T13:13:26Z","timestamp":1648818806492},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1016\/j.lungcan.2006.04.005","type":"journal-article","created":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T15:53:12Z","timestamp":1149177192000},"page":"77-83","source":"Crossref","is-referenced-by-count":14,"title":["Administration of pemetrexed immediately following gemcitabine as front-line therapy in advanced non-small cell lung cancer: A phase II trial"],"prefix":"10.1016","volume":"53","author":[{"given":"Joseph","family":"Treat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Bonomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"McCleod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neal P.","family":"Christiansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Mintzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew J.","family":"Monberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhishen","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruqin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Coleman K.","family":"Obasaju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.lungcan.2006.04.005_bib1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/(SICI)1097-0215(19990924)83:1<18::AID-IJC5>3.0.CO;2-M","article-title":"Estimates of the worldwide mortality from 25 cancers in 1990","volume":"83","author":"Pisani","year":"1999","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2006.04.005_bib2","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/00001622-199303000-00010","article-title":"Screening, diagnosis, and staging of lung cancer","volume":"5","author":"Shepherd","year":"1993","journal-title":"Curr Opin Oncol"},{"issue":"9","key":"10.1016\/j.lungcan.2006.04.005_bib3","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0954-6111(05)80061-7","article-title":"Chemotherapy for advanced non-small-cell lung cancer","volume":"88","author":"Walling","year":"1994","journal-title":"Respir Med"},{"issue":"2","key":"10.1016\/j.lungcan.2006.04.005_bib4","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.lungcan.2006.04.005_bib5","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1200\/JCO.2002.02.068","article-title":"Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer","volume":"20","author":"Scagliotti","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2006.04.005_bib6","doi-asserted-by":"crossref","first-page":"7025","DOI":"10.1200\/jco.2005.23.16_suppl.lba7025","article-title":"A randomized phase III trial of gemcitabine (G) in combination with carboplatin (C) or paclitaxel (P) versus paclitaxel plus carboplatin in advanced (stage IIIB, IV) Non-Small Cell Lung Cancer (NSCLC): update of the Alpha Oncology trial (A1-99002L)","volume":"23","author":"Treat","year":"2005","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"2 Suppl 6","key":"10.1016\/j.lungcan.2006.04.005_bib7","first-page":"42","article-title":"Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis","volume":"26","author":"Mendelsohn","year":"1999","journal-title":"Semin Oncol"},{"issue":"2 Suppl 6","key":"10.1016\/j.lungcan.2006.04.005_bib8","first-page":"68","article-title":"Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs","volume":"26","author":"Schultz","year":"1999","journal-title":"Semin Oncol"},{"issue":"10","key":"10.1016\/j.lungcan.2006.04.005_bib9","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1023\/A:1008372529239","article-title":"Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: an NCIC Clinical Trials Group study","volume":"10","author":"Cripps","year":"1999","journal-title":"Ann Oncol"},{"issue":"6 Suppl 18","key":"10.1016\/j.lungcan.2006.04.005_bib10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1053\/sonc.2002.37472","article-title":"Pemetrexed in pancreatic cancer","volume":"29","author":"Kindler","year":"2002","journal-title":"Semin Oncol"},{"issue":"2","key":"10.1016\/j.lungcan.2006.04.005_bib11","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3816\/CBC.2005.n.016","article-title":"Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer","volume":"6","author":"O'Shaughnessy","year":"2005","journal-title":"Clin Breast Cancer"},{"issue":"6 Suppl 18","key":"10.1016\/j.lungcan.2006.04.005_bib12","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1053\/sonc.2002.37476","article-title":"Pemetrexed in bladder, head and neck, and cervical cancers","volume":"29","author":"Paz-Ares","year":"2002","journal-title":"Semin Oncol"},{"issue":"1","key":"10.1016\/j.lungcan.2006.04.005_bib13","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3816\/CBC.2001.n.010","article-title":"Activity of pemetrexed (ALIMTA, multitargeted antifolate, LY231514) in metastatic breast cancer patients previously treated with an anthracycline and a taxane: an interim analysis","volume":"2","author":"Spielmann","year":"2001","journal-title":"Clin Breast Cancer"},{"issue":"3","key":"10.1016\/j.lungcan.2006.04.005_bib14","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1023\/A:1025480914273","article-title":"A phase II trial of pemetrexed in patients with metastatic renal cancer","volume":"21","author":"Thodtmann","year":"2003","journal-title":"Invest New Drugs"},{"issue":"14","key":"10.1016\/j.lungcan.2006.04.005_bib15","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.lungcan.2006.04.005_bib16","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","article-title":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy","volume":"22","author":"Hanna","year":"2004","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.lungcan.2006.04.005_bib17","first-page":"545","article-title":"Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy","volume":"1","author":"Niyikiza","year":"2002","journal-title":"Mol Cancer Ther"},{"issue":"Suppl 6","key":"10.1016\/j.lungcan.2006.04.005_bib18","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/00001813-199512006-00002","article-title":"Preclinical characteristics of gemcitabine","volume":"6","author":"Plunkett","year":"1995","journal-title":"Anticancer Drugs"},{"issue":"2","key":"10.1016\/j.lungcan.2006.04.005_bib19","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0959-8049(95)00444-0","article-title":"Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study","volume":"32A","author":"Gatzemeier","year":"1996","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.lungcan.2006.04.005_bib20","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1023\/A:1008207731111","article-title":"Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer","volume":"8","author":"Manegold","year":"1997","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.lungcan.2006.04.005_bib21","first-page":"1016","article-title":"Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts","volume":"6","author":"Teicher","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"15","key":"10.1016\/j.lungcan.2006.04.005_bib22","first-page":"3671","article-title":"Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma","volume":"59","author":"Tonkinson","year":"1999","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.lungcan.2006.04.005_bib23","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2000.18.8.1748","article-title":"Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors","volume":"18","author":"Adjei","year":"2000","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.lungcan.2006.04.005_bib24","doi-asserted-by":"crossref","first-page":"5929","DOI":"10.1200\/JCO.2005.13.953","article-title":"Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer","volume":"23","author":"Ma","year":"2005","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.lungcan.2006.04.005_bib25","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1158\/1078-0432.CCR-04-0218","article-title":"Phase II study of pemetrexed\u2013gemcitabine combination in patients with advanced-stage non-small cell lung cancer","volume":"10","author":"Monnerat","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.lungcan.2006.04.005_bib26","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1007\/s00280-004-0950-7","article-title":"A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors","volume":"55","author":"Dy","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.lungcan.2006.04.005_bib27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1016\/j.lungcan.2006.04.005_bib28","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatement in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.lungcan.2006.04.005_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.lungcan.2006.04.005_bib30","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2307\/2281868","article-title":"Nonparametric estimation of incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"issue":"1","key":"10.1016\/j.lungcan.2006.04.005_bib31","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0360-3016(99)00559-3","article-title":"Common toxicity criteria: version 2.0 an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy","volume":"47","author":"Trotti","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4 Suppl 1","key":"10.1016\/j.lungcan.2006.04.005_bib32","doi-asserted-by":"crossref","first-page":"133S","DOI":"10.1378\/chest.117.4_suppl_1.133S","article-title":"Evolution of cisplatin-based chemotherapy in non-small cell lung cancer: a historical perspective and the eastern cooperative oncology group experience","volume":"117","author":"Johnson","year":"2000","journal-title":"Chest"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500206001826?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500206001826?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,19]],"date-time":"2019-04-19T00:02:50Z","timestamp":1555632170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500206001826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["S0169500206001826"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2006.04.005","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2006,7]]}}}